Product image of Omelia (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate) supplied by GNH India

Omelia

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate
Origin:
EU

Omelia (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan medoxomil, Hydrochlorothiazide and Amlodipine besilate, the active ingredients in Omelia, are an angiotensin II receptor blocker, thiazide diuretic and calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adults.

GNH India supplies Omelia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Omelia is a fixed‑dose combination that targets the renin‑angiotensin system, sodium balance and vascular smooth‑muscle tone to control high blood pressure.

  • Hypertension: provides sustained reduction of systolic and diastolic blood pressure in patients with essential hypertension.

How It Works

  • Olmesartan medoxomil blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release; hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion; amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, producing arterial vasodilation. The combined actions lower peripheral resistance and plasma volume, resulting in blood‑pressure reduction.

Side Effects

Common Side Effects

  • Dizziness: transient light‑headedness, especially after the first dose.
  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or lower legs.
  • Flushing: warm sensation with reddening of skin.
  • Fatigue: general tiredness.
  • Increased urination: due to diuretic effect.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure causing fainting.
  • Electrolyte imbalance: notably low potassium or sodium levels.
  • Acute kidney injury: rise in serum creatinine.
  • Angioedema: swelling of face, lips or throat.
  • Pancreatitis: abdominal pain with elevated enzymes.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline blood pressure, renal function and electrolyte status.

  • Monitor blood pressure: adjust therapy if target values are not reached.
  • Check renal function: periodic serum creatinine and eGFR measurements.
  • Assess electrolytes: especially potassium and sodium levels.
  • Avoid use in severe hepatic impairment: dose adjustment may be required.
  • Counsel patients on orthostatic dizziness: advise slow position changes.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Omelia may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Aliskiren: combined renin‑angiotensin blockade can cause severe hypotension and renal failure.
  • Potassium‑sparing diuretics: risk of hyperkalemia.
  • NSAIDs: may blunt antihypertensive effect and worsen renal function.
  • Cyclosporine: increased nephrotoxicity.
  • Lithium: elevated lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: additive blood‑pressure lowering; monitor for hypotension.
  • Other antihypertensives: may require dose adjustment.
  • CYP3A4 inhibitors (e.g., erythromycin): increase amlodipine levels.
  • CYP3A4 inducers (e.g., rifampin): reduce amlodipine exposure.
  • Antidiabetic agents: enhanced hypoglycaemic effect; monitor glucose.

Frequently Asked Questions

Omelia is a prescription oral tablet that combines olmesartan medoxomil, hydrochlorothiazide and amlodipine besilate to treat hypertension. The three agents work together to lower blood pressure by reducing vascular resistance, decreasing fluid volume and promoting arterial dilation.

Olmesartan blocks angiotensin II AT1 receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urine output and lowering plasma volume. Amlodipine blocks L‑type calcium channels in vascular smooth muscle, causing arterial vasodilation. Together they provide a synergistic antihypertensive effect.

The specific dose of Omelia is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function and concomitant therapies. Only a qualified healthcare professional should set the dosage and adjust it as needed.

Safety of Omelia in pregnancy or lactation has not been established. The drug class, especially the ARB component, is generally contraindicated in the second and third trimesters. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their physician.

To order Omelia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, Omelia offers a fixed‑dose triple combination that simplifies regimens, improves adherence and targets three complementary pathways. It can be more convenient than prescribing separate tablets of an ARB, a thiazide diuretic and a calcium‑channel blocker, while delivering comparable blood‑pressure control.

Omelia tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Omelia is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, electrolyte disturbances (especially low potassium), acute kidney injury, angioedema and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden weakness, or a rash that spreads.

Omelia should be avoided in patients with known hypersensitivity to any of its components, severe renal or hepatic impairment, and in pregnant women during the second and third trimesters. Clinicians should also exercise caution in individuals with low baseline blood pressure or electrolyte abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT